Clostridium difficile infection

Current and emerging therapeutics

Angie M. Jarrad, Mark A. T. Blaskovich, Dena Lyras, Matthew A. Cooper

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Clostridium difficile infection (CDI) has been identified as a significant threat to human health in the twenty-first century. Patients with CDI experience diarrhea, gastrointestinal pain, and colonic inflammation that can be life-threatening. Antibiotic therapy is successful at treating the majority of patients with CDI, but an increased number of CDI cases over the last 15 years, including severe and recurrent disease, is problematic and must be addressed with a multifaceted approach. Cleaning and infection prevention protocols are necessary to eradicate C. difficile spores and minimize both disease transmission and recurrent infection. Appropriate antibiotic treatment with metronidazole, vancomycin, or fidaxomicin should be selected based on consideration of the disease severity, relative cost-benefit, and likelihood of treatment failure. When antibiotics fail, treatment of severe, recurrent CDI with fecal microbiota transplantation (FMT) may be justified. While caution is warranted due to the unknown long-term side effects of FMT, clinical evidence has shown excellent patient outcomes. However, difficulties associated with the lack of a standardized, FDA-approved prescription treatment must be overcome before FMT can be considered a mainstay treatment. Surgery has a role for treatment of severe fulminant CDI which is not improving with medical management. Research and development is focused on preventing infections, improving patient outcomes, and reducing recurrent disease. C. difficile-specific antibiotics and biotherapeutic approaches such as vaccines and human monoclonal antibodies currently in phase III clinical trials offer hope for improved treatment options available in the near future.
Original languageEnglish
Pages (from-to)317-334
Number of pages18
JournalCurrent Treatment Options in Infectious Diseases
Volume7
Issue number4
DOIs
Publication statusPublished - Dec 2015

Keywords

  • clostridium difficile
  • infection
  • treatment
  • fecal transplant
  • antibiotics
  • biologics
  • surgery
  • pediatric
  • antibiotic resistance
  • vancomycin
  • metronidazole
  • fidaxomicin
  • spore
  • microbiota

Cite this

Jarrad, Angie M. ; Blaskovich, Mark A. T. ; Lyras, Dena ; Cooper, Matthew A. / Clostridium difficile infection : Current and emerging therapeutics. In: Current Treatment Options in Infectious Diseases. 2015 ; Vol. 7, No. 4. pp. 317-334.
@article{8150d941e8b6423eb85c345114edfc50,
title = "Clostridium difficile infection: Current and emerging therapeutics",
abstract = "Clostridium difficile infection (CDI) has been identified as a significant threat to human health in the twenty-first century. Patients with CDI experience diarrhea, gastrointestinal pain, and colonic inflammation that can be life-threatening. Antibiotic therapy is successful at treating the majority of patients with CDI, but an increased number of CDI cases over the last 15 years, including severe and recurrent disease, is problematic and must be addressed with a multifaceted approach. Cleaning and infection prevention protocols are necessary to eradicate C. difficile spores and minimize both disease transmission and recurrent infection. Appropriate antibiotic treatment with metronidazole, vancomycin, or fidaxomicin should be selected based on consideration of the disease severity, relative cost-benefit, and likelihood of treatment failure. When antibiotics fail, treatment of severe, recurrent CDI with fecal microbiota transplantation (FMT) may be justified. While caution is warranted due to the unknown long-term side effects of FMT, clinical evidence has shown excellent patient outcomes. However, difficulties associated with the lack of a standardized, FDA-approved prescription treatment must be overcome before FMT can be considered a mainstay treatment. Surgery has a role for treatment of severe fulminant CDI which is not improving with medical management. Research and development is focused on preventing infections, improving patient outcomes, and reducing recurrent disease. C. difficile-specific antibiotics and biotherapeutic approaches such as vaccines and human monoclonal antibodies currently in phase III clinical trials offer hope for improved treatment options available in the near future.",
keywords = "clostridium difficile, infection, treatment, fecal transplant, antibiotics, biologics, surgery, pediatric, antibiotic resistance, vancomycin, metronidazole, fidaxomicin, spore, microbiota",
author = "Jarrad, {Angie M.} and Blaskovich, {Mark A. T.} and Dena Lyras and Cooper, {Matthew A.}",
year = "2015",
month = "12",
doi = "10.1007/s40506-015-0062-4",
language = "English",
volume = "7",
pages = "317--334",
journal = "Current Treatment Options in Infectious Diseases",
issn = "1534-6250",
publisher = "Springer-Verlag London Ltd.",
number = "4",

}

Clostridium difficile infection : Current and emerging therapeutics. / Jarrad, Angie M.; Blaskovich, Mark A. T.; Lyras, Dena; Cooper, Matthew A.

In: Current Treatment Options in Infectious Diseases, Vol. 7, No. 4, 12.2015, p. 317-334.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Clostridium difficile infection

T2 - Current and emerging therapeutics

AU - Jarrad, Angie M.

AU - Blaskovich, Mark A. T.

AU - Lyras, Dena

AU - Cooper, Matthew A.

PY - 2015/12

Y1 - 2015/12

N2 - Clostridium difficile infection (CDI) has been identified as a significant threat to human health in the twenty-first century. Patients with CDI experience diarrhea, gastrointestinal pain, and colonic inflammation that can be life-threatening. Antibiotic therapy is successful at treating the majority of patients with CDI, but an increased number of CDI cases over the last 15 years, including severe and recurrent disease, is problematic and must be addressed with a multifaceted approach. Cleaning and infection prevention protocols are necessary to eradicate C. difficile spores and minimize both disease transmission and recurrent infection. Appropriate antibiotic treatment with metronidazole, vancomycin, or fidaxomicin should be selected based on consideration of the disease severity, relative cost-benefit, and likelihood of treatment failure. When antibiotics fail, treatment of severe, recurrent CDI with fecal microbiota transplantation (FMT) may be justified. While caution is warranted due to the unknown long-term side effects of FMT, clinical evidence has shown excellent patient outcomes. However, difficulties associated with the lack of a standardized, FDA-approved prescription treatment must be overcome before FMT can be considered a mainstay treatment. Surgery has a role for treatment of severe fulminant CDI which is not improving with medical management. Research and development is focused on preventing infections, improving patient outcomes, and reducing recurrent disease. C. difficile-specific antibiotics and biotherapeutic approaches such as vaccines and human monoclonal antibodies currently in phase III clinical trials offer hope for improved treatment options available in the near future.

AB - Clostridium difficile infection (CDI) has been identified as a significant threat to human health in the twenty-first century. Patients with CDI experience diarrhea, gastrointestinal pain, and colonic inflammation that can be life-threatening. Antibiotic therapy is successful at treating the majority of patients with CDI, but an increased number of CDI cases over the last 15 years, including severe and recurrent disease, is problematic and must be addressed with a multifaceted approach. Cleaning and infection prevention protocols are necessary to eradicate C. difficile spores and minimize both disease transmission and recurrent infection. Appropriate antibiotic treatment with metronidazole, vancomycin, or fidaxomicin should be selected based on consideration of the disease severity, relative cost-benefit, and likelihood of treatment failure. When antibiotics fail, treatment of severe, recurrent CDI with fecal microbiota transplantation (FMT) may be justified. While caution is warranted due to the unknown long-term side effects of FMT, clinical evidence has shown excellent patient outcomes. However, difficulties associated with the lack of a standardized, FDA-approved prescription treatment must be overcome before FMT can be considered a mainstay treatment. Surgery has a role for treatment of severe fulminant CDI which is not improving with medical management. Research and development is focused on preventing infections, improving patient outcomes, and reducing recurrent disease. C. difficile-specific antibiotics and biotherapeutic approaches such as vaccines and human monoclonal antibodies currently in phase III clinical trials offer hope for improved treatment options available in the near future.

KW - clostridium difficile

KW - infection

KW - treatment

KW - fecal transplant

KW - antibiotics

KW - biologics

KW - surgery

KW - pediatric

KW - antibiotic resistance

KW - vancomycin

KW - metronidazole

KW - fidaxomicin

KW - spore

KW - microbiota

UR - http://download.springer.com/static/pdf/818/art%253A10.1007%252Fs40506-015-0062-4.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs

U2 - 10.1007/s40506-015-0062-4

DO - 10.1007/s40506-015-0062-4

M3 - Review Article

VL - 7

SP - 317

EP - 334

JO - Current Treatment Options in Infectious Diseases

JF - Current Treatment Options in Infectious Diseases

SN - 1534-6250

IS - 4

ER -